Tower Research Capital LLC (Trc) Protagonist Therapeutics, Inc Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 360 shares of PTGX stock, worth $14,648. This represents 0.0% of its overall portfolio holdings.
Number of Shares
360
Previous 14,676
97.55%
Holding current value
$14,648
Previous $508,000
96.85%
% of portfolio
0.0%
Previous 0.01%
Shares
29 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$238 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$234 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$221 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$172 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$130 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...